Covid 19 Vaccine Supply Agreement

In a next phase, the dashboard will be expanded to provide information on progress towards the COVAX facility`s goal of obtaining 2 billion doses of vaccine by the end of 2021. It will also provide information on the status of procurement and supplies by UNICEF and other national and institutional buyers participating in the COVAX Facility. "We thank the South Korean government for planning the fall 2022 recycling season with this supply agreement for our COVID-19 vaccine and mRNA booster," said Stéphane Bancel, President and CEO of Moderna. "We remain committed to ending the COVID-19 pandemic. » Forward-Looking Statements This press release contains certain forward-looking statements regarding Valneva`s business, including progress, timing, design, data readings, expected results and completion of clinical trials for VLA2001. Although Valneva`s actual results or developments are consistent with the forward-looking statements contained in this press release, such results or developments of Valneva may not be indicative of future results. In some cases, you may identify forward-looking statements by words such as "could", "should", "may", "expects", "anticipates", "believes", "intends", "estimates", "aims", "targets" or similar words. These forward-looking statements are based on Valneva`s current expectations as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that could cause actual results, performance or achievements to differ materially from future results, performance or achievements expressed or implied by such forward-looking statements. can be brought.

In particular, Valneva`s expectations could be affected, among other things, by uncertainties related to vaccine development and manufacturing, unexpected results of clinical trials, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, the ability to obtain or maintain patents or other protected intellectual property protections. the termination of existing contracts, including, but not limited to, HMG`s supply agreement, and the impact of the COVID-19 pandemic, the occurrence of which could significantly affect Valneva`s business, financial condition, prospects and results of operations. Given these risks and uncertainties, there can be no assurance that any forward-looking statements made in this presentation will be effectively implemented. Valneva provides the information contained in this press release as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. SCB-2019 (CpG 1018/alum), clover`s COVID-19 vaccine candidate, is expected to be one of the first protein-based COVID-19 vaccines to be commercialized globally through the COVAX facility. Using the trimer tag technology platform™, Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S protein (called S-trimer™) based on the original strain of the SARS-CoV-2 virus. Clover developed our COVID-19 vaccine candidate by combining SCB-2019 with Dynavax`s advanced cpG 1018 adjuvant and aluminum hydroxide (alum). "I would like to thank our partners at Gavi and COVAX for their work and collaboration in reaching this agreement. This is another important step as we work to ensure that people around the world have access to our COVID-19 vaccine as soon as possible," said Stéphane Bancel, President and CEO of Moderna. "We are proud that our agreement is the largest direct sourcing agreement with COVAX among authorized U.S. suppliers.

We remain committed to implementing a comprehensive strategy to ensure that low-income countries have access to our vaccine as we seek to end the pandemic around the world. » Answers to the most common questions about coronavirus vaccines Out of 30. In June 2021, Clover announced an Advance Purchase Agreement (APA) with GAVI, the Vaccine Alliance, to provide up to 414 million doses of SCB-2019 (CpG 1018/alum) for purchase through the COVAX Facility until a list of World Health Organization (WHO) emergency rooms is available. The LTA will implement abscond and provide COVAX participating countries with access to Clover`s COVID-19 vaccine candidates through UNICEF once the vaccine candidate has received a WHO emergency list. In the 10 years since its inception, Moderna has grown from a scientific research company advancing messenger RNA (mRNA) programs to a company with a diversified clinical portfolio of vaccines and therapeutics in six modalities, a broad portfolio of intellectual property in areas such as the formulation of mRNAs and lipid nanoparticles, and an integrated production facility. which enables both clinical and commercial production on a large scale and at unprecedented speed. Moderna maintains alliances with a wide range of governments and domestic and foreign business partners, which has allowed for the pursuit of both groundbreaking science and rapid scaling up of manufacturing. More recently, Moderna`s capabilities have come together to enable the authorized use of one of the oldest and most effective vaccines against the COVID-19 pandemic. CAMBRIDGE, Mass., Dec.

10, 2021--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MNR), a pioneering biotechnology company in messenger RNA (mRNA) therapies and vaccines, today announced an amendment to its existing contract with Gavi, the Vaccine Alliance, to deliver 20 million doses to COVAX by December 31, 2021, for a total of 54 million doses to be made available to COVAX in 2021. to accelerate. Deliveries to COVAX Advance Market Commitment (AMC) countries have already begun. About the COVAX Facility COVAX is the vaccine pillar of the COVID-19 Tools Access Accelerator (ACT), a groundbreaking global collaboration to accelerate the development, production and equal access to COVID-19 tests, treatments and vaccines. COVAX is jointly led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO. The goal is to accelerate the development and production of COVID-19 vaccines and ensure fair and equitable access for all countries around the world. UNICEF, in collaboration with the PAHO Revolving Fund, is leading efforts to procure and administer doses of COVID-19 vaccines on behalf of the COVAX Facility. .